TEDA Enterprises Leading Tianjin Nucleic Acid Vaccine and Drug Innovation Consortium Approved for Establishment

Tianjin Municipal Science and Technology Bureau recently announced the List of Proposed 2024 Tianjin Municipal Innovation Consortia, on which the Tianjin Nucleic Acid Vaccine and Drug Innovation Consortium was approved for establishment. The consortium is led by TEDA-based CanSino Biologics and jointly established by the Tianjin International Joint Academy of Biomedicine, CosyChem Technology (Tianjin) Co., Ltd., and many other enterprises, universities, and research institutes from TEDA and Tianjin, with rich advanced technologies in nucleic acid vaccines and drugs. Centering on the nucleic acid industry in Tianjin, the consortium will build an entire nucleic acid industrial chain covering nucleic acid vaccines, innovative drugs, medical devices and equipment, raw materials, CMC, CRO, and evaluation, to accelerate the construction of an innovative nucleic acid drug system and create China’s top-tier platform for nucleic acid vaccine and drug innovation. It plans to develop innovative nucleic acid vaccine and drug pipelines as a key focus to create a mature model for implementing the industrialization of nucleic acid drugs and provide a strong regional demonstration effect.

As a future-oriented biopharmaceutical industry, nucleic acid drugs are a propellor for promoting Tianjin’s advanced manufacturing sector and new quality productive forces. In 2022, TEDA Administrative Commission together with local nucleic acid enterprises, initiated the Tianjin (TEDA) Nucleic Acid Industry Alliance. The alliance now includes 37 member organizations, covering areas such as the R&D, production, service outsourcing, and auxiliary equipment of nucleic acid drug enterprises along the industrial chain. It has established an operating mechanism involving the government, major universities, state-owned capital platforms, and leading enterprises, to achieve shared benefits through consultation, collaboration and discussion, further accelerating the development and expansion of the nucleic acid drug industry in TEDA.